Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
A.-r. Collier, J. Miller, N. Hachmann, K. McMahan, J. Liu, E. Bondzie, L. Gallup, M. Rowe, E. Shonberg, S. Thai, J. Barrett, E. Borducchi, E. Bouffard, C. Jacob-Dolan, C. Mazurek, A. Mutoni, O. Powers, M. Sciacca, N. Surve, H. VanWyk, C. Wu, D. Barouch
Abstract
Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced mRNA vaccine efficacy against both symptomatic infection and severe disease. Bivalent mRNA boosters expressing the Omicron BA.5 and ancestral WA1/2020 Spike proteins have been developed and approved, because BA.5 is currently the dominant SARS-CoV-2 variant and substantially evades neutralizing antibodies (NAbs). Our data show that BA.5 NAb titers were comparable following monovalent and bivalent mRNA boosters.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1
M. E. Davis-Gardner, L. Lai, … M. S. Suthar·bioRxiv·Oct 31, 2022
- Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron subvariants BA.2, BA.2.12.1 and BA.5
- SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster
Q. Wang, A. D. Bowen, … D. D. Ho·bioRxiv·Feb 13, 2023
- Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
S. M. Scheaffer, D. Lee, … M. S. Diamond·bioRxiv·Sep 12, 2022
- Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants
P. QU, J. N. Faraone, … S.-L. Liu·bioRxiv·Jul 21, 2022
- SARS-CoV-2 Neutralizing Antibodies Following a Second BA.5 Bivalent Booster